34 results about "Basal ganglia" patented technology

The invention provides a transcranial multimodal electrical stimulation therapeutic apparatus and a use method thereof. The therapeutic apparatus includes an electric stimulation signal control device, an electric stimulation signal generating device and a headset electric stimulation current output device, wherein the headset electric stimulation current output device is provided with two or moreelectrodes, and the electrodes on the headset electric stimulation current output device correspond to governor meridian acupoints of the head. The use method of the therapeutic apparatus includes the following steps that 1, the electric stimulation signal control device sets an electric stimulation signal parameter; 2, the electric stimulation signal generating device outputs an electric stimulation signal according to the signal parameter; 3, the headset electric stimulation current output device outputs the current. The therapeutic apparatus can achieve the treatment of non-invasive transcranial multimodal electrical stimulation, avoid surgical traumas and effectively regulate the abnormal synchronous oscillation of 'a cortex-basal ganglia loop', an effective stimulation loop is formed, and the good therapeutic effect is achieved.

A computer-implemented model of the central nervous system includes at least one of a basal ganglia portion, a cerebral cortex portion coupled to the basal ganglia portion, or a cerebellum portion coupled to the cerebral cortex. Each one of the basal ganglia portion, the cerebral cortex portion, and the cerebellum portion is comprised of respective elements representative of real neuroanatomical structures of a central nervous system and the respective elements are adapted to perform functions representative of real neuroanatomical functions of the central nervous system. At least one of the basal ganglia portion, the cerebral cortex portion, or the cerebellum portion is adapted to control a plant.

Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein “R1”, “RA-1”, “R2”, “R3”, and “Het” are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. [Formula should be inserted here] The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor.; Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

One embodiment is directed to a system for controllably managing motor function in the central nervous system of a patient having a targeted tissue structure that has been genetically modified to have light sensitive protein, comprising a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure; a light source configured to provide light to the light delivery element; and a controller operatively coupled to light source; wherein the targeted tissue structure is a portion of the basal ganglia of the patient; and wherein the controller is configured to be automatically operated to illuminate the targeted tissue structure with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light sensitive protein to the radiation.

The invention provides a method for labeling human body model atlases for diagnosis. The method includes (1) dividing and labeling sub-regions, and dividing the central nervous system into the main sub-region of the telencephalon, the main sub-region of the hippocampus, the main sub-region of the basal nucleus, and the thalamus according to functional units. Main divisions, cerebellum main divisions, brainstem main divisions, spinal cord main divisions, further divide the nervous tissue into divisions or parts in the telencephalon main division, hippocampus main division, basal nucleus main division, thalamus main division and cerebellum main division, and then Partitions or parts are divided into several layers or blocks, and sub-regions are marked by layers and blocks. In the main spinal cord partition, the gray matter is first divided into 32 gray matter columns, and then each gray matter column is divided into upper and lower sections from different positions. (2) draw the atlas, divide the human body into 131 parts, and draw the corresponding position relationship diagram of the human body parts in each sub-division; (3) draw the atlas on each marked sub-division of the model above and marked.

The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the subthalmic nucleus of the basal ganglia, mesaphilia and thalamus.

The invention provides a transcranial magnetic therapeutic instrument for computer diseases, comprising a field effect cap which can be worn on head, field effect cap internally being distributed with electrodes and at least one electromagnet; the instrument further comprises an electroencephalographic simulative generator, and the electroencephalographic simulative generator is respectively connected with the electromagnet and the electrodes via conducting wires. In the invention, nerve cell nucleus of intracephalic basal ganglia part can be self-excited by a stereoscopic superposition alternating magnetic field transcranially magnetically formed at intracephalic deep part and a weak induced current formed at a specific part of intracephalic deep part; and the transcranial magnetic effect is strengthened when the nerve cell nucleus transcranially pass through basal ganglia part. The invention is not an interventional therapy but can achieve the functions of stimulating and recoveringneurotransmitters of nerve cell nucleus of intracephalic basal ganglia part such as autocrine dopamine, and is applied to encephalopathic therapy such as Parkinson, encephalatrophy, epileptics and gork; the effects exceed that of a brain pacemaker, thereby overcoming the disadvantages of pharmacotherapy and surgical therapy; and the therapeutic instrument can be used in hospital, and is more applied to treatment of patients at home.

The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.

The invention provides a deep brain stimulation FPGA experimental platform of a basal ganglia and thalamencephalon network for the parkinson's disease. The experimental platform comprises an FPGA development board and an upper computer, which are connected with each other; the FPGA development board is used for realizing a basal ganglia and thalamencephalonneuron network model and a deep brain stimulation controller; the upper computer is used for designing an upper computer software interface and being communicated with the FPGA development board. The experimental platform has the benefits that as an animal-free experiment means of a biological neural network, and on the basis of the high-speed computation FPGA neuron network, the experimental platform realizes the modeling of the neuron network of a complex parkinson's disease focus area, and the neuron network model can be consistent with real biological neuron on a time scale. The platform provides a visual research platform, closer to the real neuron network, for researching the discharging mechanism of the parkinson's disease and the abnormal discharging mode of the basal ganglia and thalamencephalonneuron network controlled by deep brain stimulation, and has a significant practical value in researching the treatment of the parkinson's disease.

The invention discloses a multi-agent formation method based on behavior selection, which comprises the following steps: Step 1, setting a position-related detection revenue calculation method; Step 2, defining specific behaviors of multiple agents; Step 3, determining The number of channels of the basal ganglia, establishing a channel model of the basal ganglia, and initializing relevant parameters; Step 4, correcting the channel model parameters of the basal ganglia. Through the above method, the multi-agent formation method based on behavior selection of the present invention introduces a dynamic agent formation method based on behavior selection, which effectively solves the problem of poor robustness and reliability in existing formation detection methods. Weakness and other disadvantages, through the opening of parameters and various weight modification channels, the technical solution of this application has wider versatility, and the introduction of target detection income variables can improve the income of multi-agent detection tasks as a whole.

The invention provides a trabscranial magnetoelectric depression therapeutic apparatus, comprising a pair of earphones, a beam connected between the earphones, at least a magnet, at least a pair of electrodes and an internal circuit; wherein, the earphones and the electrodes are connected with the internal circuit. The technical proposal is as follows: trabscranial magnetoelectricity and audio signals directly act on heads and auditory systems of human; stereo superposition electric field formed in certain parts of brain by trabscranial magnet can ensure the parts to generate weak induced current so as to self stimulate the parts to secrete dopamine and restore the function of self secreting neurotransmitter such as dopamine by the parts; the trabscranial magnet directly stimulates neutral clusters of basal ganglia of thalamus, thus strengthening the effects of the trabscranial magnet; the audio signals with special rhythm act on the auditory systems of human, which can promote human to enter into meditation and tempt secretion of the neurotransmitter such as dopamine in the brain, thus further strengthening the effects of the trabscranial magnet. The trabscranial magnetoelectricity and audio signals integrate three effects into one, supplement and complement each other and promote each other, and the therapeutic effect on depression and insomnia is unreachable for any single function.

The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor. Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and / or basal ganglia, is provided.

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: “Z”, R1 and R2 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.